Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives

被引:31
作者
Esnouf, RM
Stuart, DI
DeClercq, E
Schwartz, E
Balzarini, J
机构
[1] LAB MOL BIOPHYS, OXFORD OX1 3QU, ENGLAND
[2] UNIROYAL CHEM CO INC, MIDDLEBURY, CT 06749 USA
关键词
D O I
10.1006/bbrc.1997.6552
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The (thio)carboxanilide derivatives are potent and selective inhibitors of HIV-1 reverse transcriptase (RT) and have a favourable antiviral activity spectrum. To understand better their mode of action, and to provide a structural basis for further improvement, models of RT complexed with four (thio)carboxanilide inhibitors (UC781, UC10, UC38 and UC84) have been constructed based on the X-ray structure of RT complexed with 9-chloro-TIBO. In the models, the protein conformation is similar to that of the RT-TIBO complex and the complexes are stabilised by hydrogen bonding between the inhibitors and the main chain oxygen of Lys101. Significant hydrophobic interactions include those with Leu100, Val106, Val179, Tyr188, Phe227, Leu234, and His235. The thiocarboxanilides UC781 and UC10 also make important hydrophobic interactions with Trp229. The models are consistent with the inhibitors' relative antiviral potencies and the observed resistance data. They further predict that mutations to Phe227, Trp229, or Leu234 might confer resistance. Since these are not observed, some constraining structural or functional role for these residues in the active enzyme is suggested. (C) 1997 Academic Press.
引用
收藏
页码:458 / 464
页数:7
相关论文
共 36 条
  • [1] OXATHIIN CARBOXANILIDE, A POTENT INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS REPRODUCTION
    BADER, JP
    MCMAHON, JB
    SCHULTZ, RJ
    NARAYANAN, VL
    PIERCE, JB
    HARRISON, WA
    WEISLOW, OS
    MIDELFORT, CF
    STINSON, SF
    BOYD, MR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (15) : 6740 - 6744
  • [2] ACTIVITY OF VARIOUS THIOCARBOXANILIDE DERIVATIVES AGAINST WILD-TYPE AND SEVERAL MUTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 STRAINS
    BALZARINI, J
    BROUWER, WG
    FELAUER, EE
    DECLERCQ, E
    KARLSSON, A
    [J]. ANTIVIRAL RESEARCH, 1995, 27 (03) : 219 - 236
  • [3] SUPPRESSION OF THE BREAKTHROUGH OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) IN CELL-CULTURE BY THIOCARBOXANILIDE DERIVATIVES WHEN USED INDIVIDUALLY OR IN COMBINATION WITH OTHER HIV-1 SPECIFIC INHIBITORS (IE, TSAO DERIVATIVES)
    BALZARINI, J
    PEREZPEREZ, MJ
    VELAZQUEZ, S
    SANFELIX, A
    CAMARASA, MJ
    DECLERCQ, E
    KARLSSON, A
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (12) : 5470 - 5474
  • [4] Balzarini J, 1996, MOL PHARMACOL, V49, P882
  • [5] Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors
    Balzarini, J
    Pelemans, H
    Karlsson, A
    DeClercq, E
    Kleim, JP
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (23) : 13152 - 13157
  • [6] Balzarini J, 1996, MOL PHARMACOL, V50, P394
  • [7] Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus
    Balzarini, J
    Brouwer, WG
    Dao, DC
    Osika, EM
    DeClercq, E
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (06) : 1454 - 1466
  • [8] A WELL-BEHAVED ELECTROSTATIC POTENTIAL BASED METHOD USING CHARGE RESTRAINTS FOR DERIVING ATOMIC CHARGES - THE RESP MODEL
    BAYLY, CI
    CIEPLAK, P
    CORNELL, WD
    KOLLMAN, PA
    [J]. JOURNAL OF PHYSICAL CHEMISTRY, 1993, 97 (40) : 10269 - 10280
  • [9] Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant
    Das, K
    Ding, JP
    Hsiou, Y
    Clark, AD
    Moereels, H
    Koymans, L
    Andries, K
    Pauwels, R
    Janssen, PAJ
    Boyer, PL
    Clark, P
    Smith, RH
    Smith, MBK
    Michejda, CJ
    Hughes, SH
    Arnold, E
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1996, 264 (05) : 1085 - 1100
  • [10] ANTIVIRAL THERAPY FOR HUMAN-IMMUNODEFICIENCY-VIRUS INFECTIONS
    DECLERCQ, E
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 1995, 8 (02) : 200 - 239